GSK bid undervalues Human Genome, investor says






GSK bid undervalues Human Genome, investor says



A GlaxoSmithKline logo is seen outside one of its buildings in west London, ahead of company resultsLONDON (Reuters) - GlaxoSmithKline's $2.6 billion offer for Human Genome Sciences undervalues the biotech company, according to Taube Hodson Stonex, a leading investor in the U.S. group. "The price that's been offered, although it is a big premium to where the shares were trading, is not high enough," said Mark Evans, a fund manager at Taube, which is the sixth largest investor in Human Genome with a 5.6 percent stake. GSK, Britain's biggest drugmaker, says its $13 a share offer is "full and fair" and it is the only obvious owner for the U.S. ...









Popular posts from this blog

Russian opposition leader charged with theft

Iran unveils long-range drone: state TV

The Censorship Game: Chinese Twitter Will Score User Behavior